Krka Reports Moderate Revenue Growth But Profit Declines

BMI View: BMI believes exposure to the pharmaceutical markets of Central and Eastern Europe (CEE) will benefit Krka's long-term growth potential. The Slovenian company is well placed to take advantage of the CEE and Russia's strong growth potential, while avoiding the austerity measures and price controls currently characteristic of Western European markets. Furthermore, the company will benefit from the increasing uptake of generic medicines, partly driven by governments mandating their use as a substitute for more expensive medicines.

To read the full article, please choose one of the following options: